Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,989,708
  • Shares Outstanding, K 294,800
  • Annual Sales, $ 1,830 M
  • Annual Income, $ 207,770 K
  • 60-Month Beta 0.54
  • Price/Sales 3.75
  • Price/Cash Flow 29.70
  • Price/Book 3.06
Trade EXEL with:

Options Overview Details

View History
  • Implied Volatility 43.79% ( -0.63%)
  • Historical Volatility 22.10%
  • IV Percentile 90%
  • IV Rank 66.54%
  • IV High 55.60% on 04/12/24
  • IV Low 20.31% on 06/21/23
  • Put/Call Vol Ratio 0.14
  • Today's Volume 1,199
  • Volume Avg (30-Day) 1,713
  • Put/Call OI Ratio 1.13
  • Today's Open Interest 59,874
  • Open Int (30-Day) 59,291

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 0.23
  • Number of Estimates 8
  • High Estimate 0.36
  • Low Estimate 0.16
  • Prior Year 0.12
  • Growth Rate Est. (year over year) +91.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.23 +5.11%
on 04/19/24
23.98 -2.56%
on 03/28/24
-0.34 (-1.41%)
since 03/25/24
3-Month
20.01 +16.74%
on 02/12/24
24.07 -2.93%
on 03/21/24
+1.27 (+5.77%)
since 01/25/24
52-Week
18.08 +29.23%
on 04/28/23
24.34 -4.01%
on 01/02/24
+4.51 (+23.95%)
since 04/25/23

Most Recent Stories

More News
4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

Phenomenal deals can still be found, even with the Nasdaq Composite climbing to a new all-time high.

COMP : 3.27 (-1.80%)
$NASX : 15,600.73 (-0.71%)
META : 442.86 (-10.26%)
EXEL : 23.56 (-0.63%)
S : 21.24 (-1.53%)
PINS : 32.76 (-0.27%)
2 Biotech Stocks to Buy Hand Over Fist in March

These stocks are worth buying in most months of the year.

REGN : 898.48 (-0.89%)
EXEL : 23.56 (-0.63%)
4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found.

COMP : 3.27 (-1.80%)
$NASX : 15,600.73 (-0.71%)
MA : 463.31 (+0.18%)
PUBM : 22.59 (-3.21%)
EXEL : 23.56 (-0.63%)
AMZN : 172.94 (-2.07%)
2 Stocks Under $30 to Buy and Hold

You don't need to be a millionaire to get started. Investing on a budget can work, too.

ADYEY : 12.5600 (-16.82%)
EXEL : 23.56 (-0.63%)
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END

ONCY : 1.1104 (+4.75%)
ONC.TO : 1.51 (+2.72%)
EXEL : 23.56 (-0.63%)
PFE : 25.49 (-2.97%)
BTAI : 2.58 (-4.80%)
BMY : 44.63 (-8.66%)
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

ONCY : 1.1104 (+4.75%)
ONC.TO : 1.51 (+2.72%)
EXEL : 23.56 (-0.63%)
PFE : 25.49 (-2.97%)
BTAI : 2.58 (-4.80%)
BMY : 44.63 (-8.66%)
4 Appealing Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

The growth-driven Nasdaq Composite hasn't put the 2022 bear market entirely in the rearview mirror, which means opportunistic investors can still find bargains.

COMP : 3.27 (-1.80%)
$NASX : 15,600.73 (-0.71%)
NIO : 4.14 (-0.24%)
LOVE : 21.82 (-2.72%)
EXEL : 23.56 (-0.63%)
GOOGL : 156.14 (-1.88%)
GOOG : 157.92 (-1.97%)
Exelixis (EXEL) Q4 2023 Earnings Call Transcript

EXEL earnings call for the period ending December 31, 2023.

EXEL : 23.56 (-0.63%)
Exelixis: Q4 Earnings Snapshot

Exelixis: Q4 Earnings Snapshot

EXEL : 23.56 (-0.63%)
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END

ONCY : 1.1104 (+4.75%)
ONC.TO : 1.51 (+2.72%)
EXEL : 23.56 (-0.63%)
MRTX : 58.70 (-0.17%)
LLY : 724.84 (-1.01%)
PNT : 12.50 (+0.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the...

See More

Key Turning Points

3rd Resistance Point 24.52
2nd Resistance Point 24.15
1st Resistance Point 23.93
Last Price 23.56
1st Support Level 23.34
2nd Support Level 22.97
3rd Support Level 22.75

See More

52-Week High 24.34
Last Price 23.56
Fibonacci 61.8% 21.95
Fibonacci 50% 21.21
Fibonacci 38.2% 20.47
52-Week Low 18.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar